Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Planchard

P1.08-009 Neutrophilia as Prognostic Biomarker in Locally Advanced Stage III Lung Cancer

Journal of Thoracic Oncology

English

OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients From the French National Cancer Institute Registry: Radon France Study

Journal of Thoracic Oncology

English

P1.01-18 Immunosenescence Correlates With Progression Upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients

Journal of Thoracic Oncology

English

P1.01-41 a Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

English

MA12.06 STELLAR – Final Results of a Phase 2 Trial of TTFields With Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma

Journal of Thoracic Oncology

English

P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated With Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy

Journal of Thoracic Oncology

English

P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients

Journal of Thoracic Oncology

English

P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status With Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

Journal of Thoracic Oncology

English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Planchard

P1.08-009 Neutrophilia as Prognostic Biomarker in Locally Advanced Stage III Lung Cancer

OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients From the French National Cancer Institute Registry: Radon France Study

P1.01-18 Immunosenescence Correlates With Progression Upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients

P1.01-41 a Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer

P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790m-Mutant NSCLC Patients

MA12.06 STELLAR – Final Results of a Phase 2 Trial of TTFields With Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma

P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated With Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy

P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients

P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status With Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC